LA JOLLA, Calif., July 1, 2024 /PRNewswire/ -- CalciMedica Inc.
("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage
biopharmaceutical company focused on developing novel calcium
release-activated calcium ("CRAC") channel inhibition therapies for
acute and chronic inflammatory and immunologic illnesses, today
announced that the Company is set to join the Russell
Microcap® Index at the conclusion of the
2024 Russell U.S. Indexes annual reconstitution, effective at the
open of U.S. equity markets on Monday, July
1, 2024, according to preliminary lists of additions posted
on Friday, May 24, 2024.
The annual Russell U.S. Indexes reconstitution captures the
4,000 largest U.S. stocks as of Tuesday,
April 30, 2024, ranking them by total market capitalization.
Membership in the Russell Microcap® Index, which remains
in place for one year, means automatic inclusion in the appropriate
growth and value style indexes. FTSE Russell determines membership
for its Russell indexes primarily by objective,
market-capitalization rankings and style attributes.
"Our inclusion in the Russell index is representative of the
growth that the Company has undergone since becoming a publicly
traded company in the first quarter of 2023," said Rachel Leheny, Ph.D., Chief Executive Officer of
CalciMedica. "I am grateful to all our employees at CalciMedica for
their diligent work in pursuit of our goal of delivering
much-needed therapies to patients suffering from acute and chronic
inflammatory and immunologic illnesses, while continuing to create
value for our stockholders."
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Russell's U.S. indexes serve as the
benchmark for about $10.5 trillion in
assets as of the close of December
2023. Russell indexes are part of FTSE Russell, a leading
global index provider.
Fiona Bassett, Chief Executive
Officer of FTSE Russell, an LSEG Business, commented, "Russell
indexes–now in their 40th year–continue to evolve to reflect the
dynamic U.S. economy. Annual rebalancing plays a vital role in
establishing accurate benchmarks, ensuring they correctly mirror
their designated market segments and remain unbiased in terms of
size and style."
For more information on the Russell Microcap® Index
and the Russell indexes reconstitution, go to the "Russell
Reconstitution" section on the FTSE Russell website.
About CalciMedica
CalciMedica is a clinical-stage
biopharmaceutical company focused on developing novel CRAC channel
inhibition therapies for inflammatory and immunologic diseases.
CalciMedica's proprietary technology targets the inhibition of CRAC
channels to modulate the immune response and protect against tissue
cell injury, with the potential to provide therapeutic benefits in
life-threatening inflammatory and immunologic diseases for which
there are currently no approved therapies. CalciMedica's lead
product candidate Auxora™, has demonstrated positive and
consistent clinical results in multiple completed efficacy clinical
trials. CalciMedica has completed a Phase 2b trial (called CARPO – NCT04681066) in AP with
SIRS and a Phase 2b trial (called
CARDEA – NCT04345614) in COVID pneumonia patients,
continues to support the ongoing Phase 1/2 AIPT study (called CRSPA
– NCT04195347), with data expected in 2025, and has initiated its
Phase 2 study (called KOURAGE – NCT06374797) in AKI with associated
AHRF with data expected in 2025. CalciMedica was founded by
scientists from Torrey Pines Therapeutics and the Harvard CBR
Institute for Biomedical Research, and is headquartered in
La Jolla, CA. For more
information, please visit www.calcimedica.com.
About FTSE Russell
FTSE Russell is a leading global
provider of benchmarking, analytics, and data solutions for
investors, giving them a precise view of the market relevant to
their investment process. A comprehensive range of reliable and
accurate indexes provides investors worldwide with the tools they
require to measure and benchmark markets across asset classes,
styles, or strategies.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. For over 30 years,
leading asset owners, asset managers, ETF providers and investment
banks have chosen FTSE Russell indexes to benchmark their
investment performance and create ETFs, structured products, and
index-based derivatives.
FTSE Russell is focused on applying the highest industry
standards in index design and governance, employing transparent
rules-based methodology informed by independent committees of
leading market participants. FTSE Russell fully embraces the IOSCO
Principles, and its Statement of Compliance has received
independent assurance. Index innovation is driven by client needs
and customer partnerships, allowing FTSE Russell to continually
enhance the breadth, depth and reach of its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit
https://www.lseg.com/en/ftse-russell.
Forward-Looking Statements
This communication contains
forward-looking statements which include, but are not limited to,
statements related to: CalciMedica's inclusion in the Russell
Microcap® Index; CalciMedica's business strategy;
CalciMedica's planned and ongoing clinical trials and the timing,
design, expected patient enrollment thereof and the expected timing
for the release of data from those trials; and the potential of
CalciMedica's proprietary technology to provide therapeutic
benefits in life-threatening inflammatory and immunologic diseases.
These forward-looking statements are subject to the safe harbor
provisions under the Private Securities Litigation Reform Act of
1995. CalciMedica's expectations and beliefs regarding these
matters may not materialize. Actual outcomes and results may differ
materially from those contemplated by these forward-looking
statements as a result of uncertainties, risks, and changes in
circumstances, including, but not limited to, risks and
uncertainties related to: the impact of fluctuations in global
financial markets on CalciMedica's business and the actions it may
take in response thereto; CalciMedica's ability to execute its
plans and strategies; the ability to obtain and maintain regulatory
approval for Auxora; results from clinical trials or preclinical
studies may not be indicative of results that may be observed in
the future; potential safety and other complications from Auxora;
the scope, progress and expansion of developing and commercializing
Auxora; the size and growth of the market therefor and the rate and
degree of market acceptance thereof; economic, business,
competitive, and/or regulatory factors affecting the business of
CalciMedica generally; CalciMedica's ability to protect its
intellectual property position; the impact of government laws and
regulations; and CalciMedica's financial position and need for
additional capital. Additional risks and uncertainties that could
cause actual outcomes and results to differ materially from those
contemplated by the forward-looking statements are included under
the caption "Risk Factors" in CalciMedica's Quarterly Report on
Form 10-Q for the quarter ended March 31,
2024, and elsewhere in CalciMedica's subsequent reports on
Form 10-K, Form 10-Q or Form 8-K filed with the Securities and
Exchange Commission from time to time and available at www.sec.gov.
These documents can be accessed on CalciMedica's web page at
ir.calcimedica.com/financials-filings/sec-filings. The
forward-looking statements contained herein are made as of the date
hereof, and CalciMedica undertakes no obligation to update them
after this date, except as required by law.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calcimedica-set-to-join-russell-microcap-index-302186338.html
SOURCE CalciMedica, Inc.
